An observational study in Cardiac Arrest, Extracorporeal Membrane Oxygenation and Hypoxia-Ischemia, Brain, sponsored by Sahlgrenska University Hospital. Recruiting at 1 site in Sweden. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-01-20.
Sponsored by Sahlgrenska University Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Heart Arrest with a site in Sweden — 4 open to participants now, 8 under way, none of them phase 3. Heart Arrest · Sweden.
Among the 27 studies in Heart Arrest with a site in Sweden, this one is the 7th largest by planned enrollment of the 12 observational ones that give a count, is one of 3 that started in 2010, is one of 12 observational ones, and was the 17th registered.
927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.
Browse Heart Arrest studies →4 of the 27 studies in Heart Arrest with a site in Sweden are open now. Recruiting first, the newest first:
Lund University · Sites in Sweden, Finland, Germany
Ages 18–100
Karolinska Institutet · Sites in Sweden, Italy
Ages 18+
Linkoeping University · Sites in Sweden
Ages 18+
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 700 is above the median of 200 across 376 observational studies indexed under Heart Arrest.
Median enrollment 950 across the 15 interventional studies, 850 across the 12 observational. Of the 16 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 27 have an industry lead sponsor. The 10 most frequent:
Sahlgrenska University Hospital is the lead sponsor of 264 studies on the registry; 69 are open to participants now.
Sahlgrenska University Hospital has 2 studies filed under Heart Arrest — fewer than ten, so there is no comparison to draw.
2 of the studies in Heart Arrest with a site in Sweden that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07579390Helsinki University Central HospitalEffects of Sedation, TEmperature and Pressure After Cardiac Arrest and REsuscitation on Major Adverse Kidney Events (STEPCARE-MAKE) | 2026-12 |
| NCT07017374Region SkaneProteomic Analysis of Serum Samples After Cardiac Arrest: a TTM-trial Substudy | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 27 studies in Heart Arrest with a site in Sweden, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
In ECPR, where CPR times often range from 30 to 120 minutes, only patients with good circulation during CPR survive, while non-survivors commonly suffer from anoxic brain injury. The selection process during CPR is challenging causing a general survival rate of just 2 out of 10, and the urgent need for better selection criteria has been emphasized. It it crucial to keep cardiac arrest times as short as possible, pre primed-ECMO can facilitate this.
The ECMO treatment and the long CPR times of ECPR can also affect the measurements of the neurologic prognostication guidelines after cardiac arrest, making its validity uncertain in this specific cohort. Further, the long-term neuropsychological follow-up is limited to a few patients, making it uncertain if ECPR gives the survivors good long-term life satisfaction or just a prolonged life.
Our overall aim is to optimize and improve the care pathway for ECPR patients by refining patient selection, assessing pre-primed ECMO, validating neurological prognostication guidelines, and understanding long-term outcomes and challenges faced by survivors.
Specific Aim 1: Evaluating predictors for good neurological outcomes in ECPR and to develop and validate (internally and externally) an evidence-based selection tool for ECPR.
Specific aim 2: To assess the sterility and function of pre-primed ECMO.
Specific aim 3: To evaluate the applicability of current guidelines for neurological prognostication after cardiac arrest in ECPR patients, and to assess the predictive value of individual and combined neurological tests in this specific patient population.
Specific aim 4: To determine the long-term neuropsychological outcomes, identify the problems survivors experience in daily life, and assess life satisfaction - by comprehensive follow-up visits with validated questionnaires and neuropsychology testing up to 12 years after the ECMO-treated cardiac arrest.
Specific aim 1: The aim is to develop an ECPR prognostication tool and validate its performance. In development, possible predictors for good neurological outcomes are prospectively gathered. The predictive ability of the predictors is tested in univariate and multivariable analysis, with the aim of improving patient selection for ECPR. Patients from the Gothenburg ECPR cohort are included in the development study. External validation with the ECMO patients from the Prague OHCA trial, following guidelines for validation studies, will follow, as well as external validation with further patients from Gothenburg.
Specific aim 2: Cardiohelp ECMO circuits are set up dry, followed by wet-priming and used in the ECMO treatments of the centre. The circuits are cultured at ECMO-initiation and the incidence of positive cultures is assessed. The effect of the pre-primed time on ECMO function is also assessed.
Specific aim 3: The predictive ability of the current guideline for neurological prognostication of comatose patients in the ICU after cardiac arrest, from the European Resuscitation Council, is assessed in the ECPR cohort of Gothenburg. The diagnostic performance of individual predictors as well as the total accuracy of the prediction will be assessed.
Specific aim 4: A Long-term (1-12 years) follow-up of the ECPR patients will be performed, to determine the long-term neuropsychological outcomes.
4 A: Life satisfaction after ECPR will be assessed along with anxiety, depression, fatigue, cognitive function, and physical activity. The impact of these factors on life satisfaction will also be evaluated. QUALY will be calculated.
4 B: Long-term neurocognitive function in ECPR patients will be assessed through comprehensive neuropsychological testing, using conventional CPR patients from the TTM2 trial as a control group.
The general ECMO population from 2004 of the center is included as a control group and positive cultures during their ECMO runs are documented.
ECPR Group: Patients who is put on ECMO during cardiac arrest. ECMO Group: Patients who is put on ECMO with some ongoing circulaiton
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients that is put om ECMO during cardiac arrest
Other: No intervention
Patients that is put on ECMO due to circulatory failure but not cardiac arrest
Other: No intervention
No intervention, but ECPR patients will be compared to ECMO-patients that have not had cardiac arrest
Modified Rankin scale (MRs)
Assessmenty of cognitive function. 0-6, where 0 is best.
Time frame: 1 year
Performance of ECMO oxygenator function
Oxygenator resistance, and the needed FiO2 and sweep gas flow will be assessed
Time frame: 0-60 days
Positive cultures of pre-primed ECMO circuits
ECMO circuits is pre-primed and cultures taken at the start of ECMO treatment
Time frame: 0-90 days
Predictive ability of ERC neuro prognostication guidelines on ECPR patients
Diagnostic performance and ROC analysis of individual and total ERC predictors on outcome in ECPR
Time frame: 1 year
Life Satisfaction
Visual Analog Scale 1-10. 10 is better.
Time frame: 1-12 years
Euro Qualy - 5 dimension (EQ-5D-5L) VAS
Self-perceived health status. 0-100, where higher is better.
Time frame: 3 months to 12 years
Neurocognitive function
Z-scores of verbal and visual function, episodic and visuospatial memory , processing speed and executive functions. 0 represents standardized population norm and ± 1 represent one standard deviation from that.
Time frame: 3 months to 12 years after the ECPR-treatment
Positive blood Cultures
Infection rates in ECMO-patients
Time frame: 1 month
MoCA
Assess cognitive function, higher is better. 0-30 where higher is better
Time frame: 3 months to 12 years after the ECPR treatment
Hospital Anxiety and Depression Scale (HADS)
Two sub scales 0-21 which assess anxiety and depression, higer is worse
Time frame: 3 months to 12 years
Mental Fatigue Scale
Assess fatigue 0-42 points. Higher is worse
Time frame: 3 months to 12 years
modified Rankin Scale
physical function from 0-6 where 0 is best
Time frame: 3 months to 12 years
Actual physical activity
Days per seven days with more than 30 minutes of physical activity
Time frame: 3 months to 12 years
Cost
The in hospital cost of the treatment for the patients, in Swedish kronor.
Time frame: 3 month
Short Form -36 (SF-36)
Quality of life. 8 scaled scores from 0-100, where 100 is best.
Time frame: 1-7 years
Trailmaking test
Assessmenty of cognitive function. Shorter time is better.
Time frame: 1-7 years
New York heart association class (NYHA class)
Assessment of physical function.1-4, where 1 is best
Time frame: 1-7 years
Euro-Qualy-5D-5L
Quality of life assessment, higher is better. Swedish value set -0.33 - 1.00
Time frame: 3 moths to 12 years
Plan to share: No
Started Jan 2010 (actual). Primary completion is estimated for Jan 2030, 240 months after the start.
Of 169 non-industry observational studies under Heart Arrest, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 96. This study's planned 240 months is above that.
Counting every sponsor, half of 176 studies reached it within 41 months; a quarter within 18 and three quarters within 90.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sahlgrenska University Hospital →